Novo Nordisk Investigational Site

Aberdeen AB25 2ZN

0 studies enrolling now · 13 studies all time

What they study most

Chronic Kidney Disease, Congenital Bleeding Disorder, Congenital FXIII Deficiency, Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, End-Stage Renal Disease

Studies at this site

• A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes — Completed
• Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results — Completed
• Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study — Completed
• Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes — Completed
• A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus — Completed
• Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 — Completed
• Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes — Completed
• Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes — Completed
• The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes — Completed
• The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus — Completed
• The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis — Stopped early
• Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes — Completed
• Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency — Completed